Theriva Biologics announced key progress in VIRAGE, a multinational, Phase 2b, randomized, open-label, controlled clinical trial evaluating VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) as a first-line therapy for patients with metastatic pancreatic ductal Adenocarcinoma (PDAC). Dosing in Spain initiated in January 2023 and the first patients have now received their second doses of intravenous VCN-01, which were well tolerated with a safety profile consistent with prior clinical trials. VCN-01 has been administered to over 80 patients in Phase 1 and investigator-sponsored clinical trials of different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3816 USD | +2.03% | +4.84% | -11.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.28% | 6.41M | |
+9.15% | 114B | |
+11.47% | 104B | |
-13.73% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.79% | 17.89B | |
+7.81% | 14.28B | |
+34.97% | 12.55B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics Announces Key Progress in Virage, an Ongoing, Multinational Phase 2B Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma